What are the four phases of a clinical trial?
Having enjoyed steady growth over the last several years, it’s predicted that the global clinical trials market will hit a value of $65.2 billion by 2025, and around 58% of this can be attributed to research within oncology. This is being driven by an increased demand for Clinical Research Organisations (CROs) to conduct clinical trials, a move towards personalised treatment and digitalisation of the healthcare market.
Despite the notable expansion of the market, it can take up to 15 years to get a new medicine or treatment to market because of the lengthy procedure of obtaining a licence. The process is split into distinct stages and each is thought of as a separate study where researchers are only permitted to move to the next stage once the U.S. Food and Drug Administration (FDA), Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMA) or other regulatory agency gives their approval. Here are the four phases of a clinical trial.
Phase I
Though there is sometimes a phase 0 to test whether researchers were correct about the way the body reacts to a drug, often clinical trials will start at phase I. A clinical trial refers to a study within clinical research where patients are monitored to determine the efficacy of a treatment; this can be a drug, medical device or procedure. Therefore, from the very first stage, a clinical operations team will be testing to see how the drug is broken down by the body, looking for side effects and beginning to find the optimal dosage.
Phase I ranges between several months to a year and tests the treatment on a small group of healthy patients. Once the trial is complete the drug safety associate (DSA) will submit their research to the regulatory agency at which point the FDA reports that around 7 in 10 receive approval.
Phase II
Those drugs, wearables or other treatments that pass approval at the first stage of clinical trials will progress to phase II where the focus is to test on a larger sample and typically introduce a placebo group. The placebo group - usually a randomised sample - will receive an inactive drug or a dummy treatment which allows clinical research associates (CRAs) to identify whether patients show side effects because they believe they’re receiving the treatment. Researchers can then compare the effectiveness of the treatment against the placebo group to get a clear picture of how well it works.
At this stage, clinical trial assistants (CTAs) are also assessing the safety of the treatment and monitoring any short-term adverse effects and phase II will normally span two years. The FDA reveals that the success rate at this stage is just 33%.
Phase III
At phase III, a clinical trial manager will work alongside the project manager to identify if the drug has an overall positive effect on the patient’s wellbeing. Having qualified to this stage CRO companies will recruit more patients into randomised groups to get a clearer picture of data discrepancies and therefore understand the success of the drug.
Treatments which receive approval after phase III are awarded a licence meaning that the medicine can go to market and be prescribed to the public. Over the last 10 years, US drug manufacturers have spent on average $1 billion getting their drug to market and this is partially due to rising costs associated with advancements in technology.
Read more on why you should be a project manager.
Phase IV
The fourth and final stage is tested once the drug has gone to market and is designed to understand the side effects better and establish if there are any long-term risks throughout the life span of the drug. At phase IV DSAs are evaluating the outcomes on a more wide-spread basis – generally in the thousands.
Work on some of the most exciting clinical trials with ICON
At ICON, we’re determined to be the partner of choice in drug development and this ambition sees us working on an extensive variety of projects. Take a look at our clinical operations jobs or for more insight read about the impact of Covid-19 on pharmacovigilance.
Related Content
Sign up for post alerts
ICON & You
The potential of together.
Careers that improve the lives of patients, our clients and each other. Are you ready to make a difference?
View jobsRelated jobs at ICON
Salary
Location
US, Portland, OR
Department
Full Service - Development & Commercialisation Solutions
Location
Portland
Remote Working
Office Based
Business Area
ICON Full Service & Corporate Support
Job Categories
Laboratory
Job Type
Permanent
Description
At ICON, it’s our people that set us apart. Our diverse teams enable us to become a better partner to our customers and help us to fulfil our mission to advance and improve patients’ lives. Our ‘Own I
Reference
JR117360
Expiry date
01/01/0001
Author
Frank LampartAuthor
Frank LampartSalary
Location
US, New York, NY, Farmingdale
Department
Full Service - Development & Commercialisation Solutions
Location
Farmingdale
Remote Working
Office Based
Business Area
ICON Full Service & Corporate Support
Job Categories
Laboratory
Job Type
Permanent
Description
At ICON, it’s our people that set us apart. Our diverse teams enable us to become a better partner to our customers and help us to fulfil our mission to advance and improve patients’ lives.
Reference
JR117747
Expiry date
01/01/0001
Author
Jeff ConnorAuthor
Jeff ConnorSalary
Location
United States
Department
Project Management Roles
Location
United States
Remote Working
Remote
Business Area
ICON Strategic Solutions
Job Categories
Project Management
Job Type
Permanent
Description
ICON plc is a world-leading healthcare intelligence and clinical research organization. We’re proud to foster an inclusive environment driving innovation and excellence, and we welcome you to join us
Reference
2024-109905
Expiry date
01/01/0001
Author
Melissa BennerAuthor
Melissa BennerSalary
Location
France, Paris
Department
Clinical Monitoring
Location
Paris
Lyon
Remote Working
Hybrid: Office/Remote
Business Area
ICON Full Service & Corporate Support
Job Categories
Clinical Trial Support
Job Type
Permanent
Description
InHouse CRA (Fast Track to CRA)France, Officebased in Paris or Lyon.At ICON, it’s our people that set us apart. Our diverse teams enable us to become a better partner to our customers and help us to f
Reference
JR115273
Expiry date
01/01/0001
Author
Jonathan CunliffeAuthor
Jonathan CunliffeRelated stories
Teaser label
Inside ICONContent type
BlogsPublish date
04/18/2024
Summary
Endometriosis Awareness: A Vital Cause In March, ICON, through its Networking Organization for Women (NOW) employee resource group, joined the global effort to raise awareness about endometriosis
Teaser label
IndustryContent type
BlogsPublish date
04/18/2024
Summary
Introduction to Data Management in Clinical Trials In the field of clinical research, data management plays a crucial role in ensuring the success and accuracy of clinical trials. Clinical trials
Teaser label
IndustryContent type
BlogsPublish date
04/12/2024
Summary
Introduction to the Clinical Research Supply Chain The clinical research supply chain plays a crucial role in the successful execution of clinical trials. It encompasses a complex network of activ
Recently viewed jobs
A better career. A better world. A better you.
Our people are our greatest strength, are the core of our culture and the driving force behind our success. Throughout all levels of the company, our people have a drive to succeed and a passion that ensures what we do, we do well. We help you build exciting and rewarding careers, deliver results to help bring life-changing medicine and devices to market and maintain ICON’s success as an industry leader. See all locations Read more